Detection of abnormal numbers and/or distribution of bone marrow (BM) plasma cells (PCs) on trephine biopsies can be of importance in the differential diagnosis of multiple myeloma (MM) and other PC neoplasms (1,2). CD138 expression in hematologic malignancy in bone marrow biopsy specimens is limited to nonneoplastic and neoplastic plasma cells and lymphoplasmacytic lymphoma in […]
This rabbit monoclonal antibody recognizes a protein of 36 kDa, identified as Cyclin D1 (also known as Bcl-1 or PRAD-1). Cyclin D1 is a regulatory subunit of certain protein kinases thought to advance the G1 phase of the cell cycle.15 Cyclin D1 used in tandem with CD5, CD10 and CD23 is the most reliable immunohistochemical […]
This rabbit monoclonal antibody recognizes a protein of 36 kDa, identified as Cyclin D1 (also known as Bcl-1 or PRAD-1). Cyclin D1 is a regulatory subunit of certain protein kinases thought to advance the G1 phase of the cell cycle.15 Cyclin D1 used in tandem with CD5, CD10 and CD23 is a reliable immunohistochemical marker […]
![Tonsil stained with CD19 (RM) [RM332] antibody](https://biocare.net/wp-content/uploads/3270-1.jpg)
The Biocare CD19 antibody detects CD19, a transmembrane glycoprotein of the immunoglobulin superfamily encoded by the CD19 gene and regulated by the B-cell-specific activator protein (BSAP).15 CD19 is expressed across nearly all developmental and activation-dependent stages of B-cell differentiation and serves as a key regulator of antigendependent B-cell activation.15 It is expressed in various B-cell […]
![Tonsil stained with CD137 [BLR051F] antibody](https://biocare.net/wp-content/uploads/3264.jpg)
CD137 (4-1BB), or tumor necrosis factor receptor superfamily member 9 (TNFRSF9), is a promising target for enhancing antitumor immune responses without the autoimmune side effects associated with immunotherapy approaches (1). CD137 signaling plays a significant role in multiple cells and regulates the activity of many immune cells. It can activate CD8+ T cells, induce cytokine […]
CD10, also known as common acute lymphoblastic leukemia (CALLA), has been shown to react with B and T lymphoblastic leukemia/lymphoma, follicular lymphoma, Burkitt’s lymphoma, and diffuse large B-cell lymphoma (1-3). CD10 has also been a very important marker in a panel, including CD20, CD5, CD23, cyclin D1, SOX11, BCL6 among others, to differentiate between small […]
CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses (1). The functions of CD137 in T lymphocytes include regulating activation, proliferation and apoptosis (2). CD137 helps regulate the activation of many immune cells, including CD4(+) T cells, CD8(+) T cells, dendritic cells, and natural killer […]
A fusion event involving CCND1 and IGH has been widely reported in many hematologic tumors such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia1. It is often thought of as a signpost marker for MCL,the frequency of t(11;14) for this type of lymphoma has been reported […]
CD138/syndecan-1 is an excellent marker for identifying plasma cells, as CD138 is a transmembrane heparin proteoglycan present on the surface membrane of plasma cells that remains active in formalin-fixed paraffin-embedded bone marrow sections. Other hematopoietic cells, endothelial cells and lymphoplasmacytoid lymphomas in bone marrow are CD138 negative (1). CD138 is also expressed in fibroblasts, keratinocytes […]
CD1a is a protein of 43 to 49 kDa and is expressed on dendritic cells and cortical thymocytes (1,2). CD1a [O10] staining has been shown to be useful in the differentiation of Langerhans cells from interdigitating cells. It has also proved useful for phenotyping Langerhans cell histiocytosis (2,3). CD1a may be a novel biomarker for […]
